Objective: Human papillomavirus (HPV) testing has been proposed for inclusion in the UK cervical screening programme. While testing may bring some benefits to the screening programme, testing positive for HPV, a sexually transmitted virus, may have adverse social and psychological consequences for women. The aim of this study was to examine the social and psychological impact of HPV testing in the context of cervical cancer screening.

Method: In-depth interviews generating qualitative data were carried out with 74 women participating in HPV testing in England between June 2001 and December 2003. Purposive sampling was used to ensure heterogeneity in age, ethnic group, marital status, socioeconomic background, cytology, and HPV results among participants.

Results: Testing positive for HPV was associated with adverse social and psychological consequences, relating primarily to the sexually transmitted nature of the virus and its link to cervical cancer. Women described feeling stigmatised, anxious and stressed, concerned about their sexual relationships, and were worried about disclosing their result to others. Anxiety about the infection was widespread, but the impact of testing positive varied. The psychological burden of the infection related to women’s relationship status and history, their social and cultural norms and practices around sex and relationships, and their understanding of key features of HPV.

Conclusion: HPV testing should be accompanied by extensive health education to inform women and to de-stigmatise infection with the virus to ensure that any adverse impact of the infection on women’s wellbeing is minimised.

METHOD

Participants

A total of 74 women were recruited in Manchester and London from clinical trials of HPV testing and from colposcopy clinics where HPV testing is carried out as part of routine care. Most participants had an HPV test at the same time as their routine smear, but for some, testing was offered alongside colposcopy following abnormal cytology results. All participants had received their test results (HPV and smear). Within each centre, all women had been given standardised information about HPV, although there was some variation in the detail between centres.

We used non-random, purposive sampling to ensure heterogeneity with respect to age, marital status, socioeconomic background, and cytology result. Women from three broad ethnic groups were included: white British, south Asian (including Pakistani, Indian, and east African Asian) and African Caribbean. These groups have been shown to differ in attitudes towards sexual health and uptake of cervical screening. Women who had tested positive or negative on the Digene HCII HPV test were included.

Abbreviations: CIN, cervical intraepithelial neoplasia; GPs, general practitioners; HPV, human papillomavirus; STI, sexually transmitted infections
Procedure
In-depth interviews were carried out with women, usually in their own homes. Interviews were structured around a topic guide (see table 1) which encouraged the individual to respond freely to open-ended questions relevant to their experience. The topic guide provides a flexible set of content areas to direct the interview process while allowing the participants’ experience to influence the specific content and direction of the interview. Interviews were carried out by the first and second authors and trained freelance interviewers, using a mixture of ethnic matching and mismatching. They were transcribed verbatim and translated by the interviewer where necessary.

Framework analysis was used to organise the data and identify emerging themes. The thematic framework is developed through familiarisation with a subset of transcripts. All data are summarised within the matrix to allow relationships and explanations for patterns within the data to be explored.

RESULTS
Participant characteristics are shown in table 2 and demonstrate the heterogeneity of the sample. The data were examined to understand the impact of HPV testing on women and to explore how and why the impact varied. The analysis presented here focuses mainly on the 57 women who were HPV positive. Women’s responses were clustered around two main themes, the first relating to anxiety about HPV in the context of increased risk of cervical cancer, and the second relating to the meaning, consequences, and understanding attached to the HPV infection (see table 3).

General psychological wellbeing
Women’s general response to a positive HPV test result was one of distress, anxiety, and upset. Women described feeling shocked at receiving a diagnosis of an infection of which they had little previous awareness or understanding. This was combined with anxieties about cancer risk, concerns about further investigation/treatment for cervical intraepithelial neoplasia (CIN), and worries about fertility; concerns which have been found to commonly accompany an abnormal smear result, even in the absence of HPV testing. The extent of anxiety some women described included intrusive thoughts and somatic responses to the diagnosis during the period when they first received their test results.

- “I was looking really ill. I wasn’t sleeping. It was kind of nearly every day I was thinking about it” (W23 HPV+ CIN2)

(Participant ID numbers use W, SA, and AC to denote white, south Asian, and African Caribbean women, respectively.)

Anxieties relating to cervical cancer are well described elsewhere11 12 and will not be the focus of the current paper. The following data will therefore relate specifically to issues raised by the diagnosis of HPV infection.

Concerns relating to the meaning, consequences, and understanding of HPV
Much of the concern which emerged about testing positive for HPV related to the sexually transmitted nature of the infection. This affected women across a number of social, emotional, and behavioural dimensions.

Stigma of an STI
Shock, embarrassment, and shame were common responses to the infection, with women using terms such as “unclean,” “dirty,” “cheap and nasty” to describe how they felt in response to their positive HPV result.
• “It just made me feel so dirty … there’s a sort of shame, there’s a leper type deal to it.” (W24 HPV+ normal smear)

Such reactions suggest connotations of promiscuity surrounding HPV that were linked to its mode of transmission and perceived connection with genital warts.

• “The stigma comes from it being sexually transmitted and the fact that it not only predisposes you to cancer but it predisposes you to genital warts and other things like that.” (S3A HPV+ normal smear)

Confusion between high risk HPV types and low risk genital wart types was common and was linked to use of the term “wart virus” in information provided to women about HPV, and confusion among healthcare providers themselves about the different viral types. Notably, feelings of stigma and shame were not displayed among women who were unaware that HPV is sexually transmitted, suggesting an additional burden that awareness of HPV can bring.

The stigma associated with HPV also impacted on women’s feelings about sex and their sexual relationships. Some women said they felt “dirty” and therefore sexually unattractive. Others reported feeling “infected” or that something was “growing inside them” and were worried about transmitting the infection. Some seemed to be more affected by concerns that the physical act of sex would worsen their abnormal cells. However, there were also women who were clearly aware of the route of transmission but who did not attach any stigma or personal feelings of embarrassment or shame to it. Among this group of women, common STIs such as HPV were seen an inevitable part of sexual activity.

• “A normal thing for many women to have.” (S2A HPV+ normal smear).

Guilt and blame for the cause of the HPV infection

Searching for an understanding of who caused the infection was a common response. Some women described feeling angry that a previous partner had infected them with what they perceived as a serious and carcinogenic virus. Others felt guilty that they had acquired the infection by being careless or promiscuous. Some blamed themselves for trusting someone who had only recently met. In contrast, in more established relationships where there had been openness about previous sexual relationships, the HPV was simply attributed to a previous partner and appeared to cause little problem.

• “My husband could have been the carrier or boyfriends I had before him. Or somebody afterwards. It could have been anybody. It’s not something that they’re likely to know they’ve got either. So I just thought well I have it so that’s where we are.” (W28 HPV+ mildly abnormal smear)

Disclosure

Women repeatedly described anxiety about disclosing their HPV positive test result to their partner or family and friends. For some, the stress of disclosure appeared to be the most difficult aspect of managing the HPV infection.

Disclosure to sexual partners

Women reported feeling highly anxious about informing their partner, with descriptions of “bursting into tears” and feeling intensely “guilty” and worried that they may have infected their partner with the virus.

• “I’ve infected him and this is the man I want to spend the rest of my life with … how am I going to tell him?” (W31 HPV+ CIN3)

The underlying concern about the disclosure centred on embarrassment and shame about the promiscuity attached to an STI and also a fear of being sexually rejected.

• “If I told men that I had it they might not want to have sex with me.” (W2 HPV+ CIN2)

To manage the anxiety many women chose not to tell their partner about their HPV infection, instead focusing on their abnormal cytology result which did not carry direct connotations of sexual transmission. In other cases women described being deliberately vague about how HPV was transmitted or playing up their own confusion:

• “I have told my partner that they don’t know where it comes from … obviously because he’d look at me in a different light because … he’d be like, have I got it or has she been with somebody else?” (W13 HPV+ normal smear)
Sometimes, the choice not to tell their partner was based on the information that the HPV infection had no impact on their partner and disclosure was therefore unnecessary. In other cases, women did not know what they should tell their partner and in the absence of clear advice simply elected not to say anything. This decision was motivated by women’s desire to minimise their own anxiety during an already stressful period and to avoid dealing with a difficult issue of which they had only limited understanding.

- “It seemed easier and less stressful not to tell him and it was nothing that was going to affect him physically.” (W6 HPV+ CIN1)

In contrast, where previous sexual activity was freely acknowledged and accepted, women found no difficulty in confiding in their partner, although the HPV infection was typically attributed to a previous partner.

- “He was really supportive about it. It was me saying to him it’s because I’ve been stupid and blah blah … and he was saying well maybe it’s not, how do you know?” (W35 HPV+ CIN2-3)

Disclosure to family and close friends

Women were also highly anxious about talking to family members. Some women chose not to tell anyone, others gave family and friends information only relating to their smear result rather than HPV. Again, worries around disclosure centred on concern about the stigma of an STI and its associations with promiscuity.

- “I lied, I told them irregular activity, I didn’t say HPV. I only told my sister when I knew I didn’t have it [I didn’t want people saying that I had a genital wart problem or weird STD thing … association of genital warts isn’t great.” (W4 HPV+ normal smear)

Those who did tell friends and family reported them being supportive and helpful, although a few described negative experiences.

- “My mum was like, ‘I told you so’ … it’s not something you really want to hear.” (W35 HPV+ CIN2-3)

The role of social, cultural, and religious norms around sex and relationships

Women’s norms and practices around sex and relationships emerged as an important in influencing their ability to disclose the result to others and draw on social and emotional support. This was most apparent among some of the south Asian women, particularly younger unmarried south Asian women who hid their sexual relationships from their parents. In this context attendance for cervical screening per se was seen as an indicator of sexual activity and was hidden.

- “I don’t even know if my mum’s ever had a smear test and she must have done she’s has three kids. But it’s not something we ever spoke about. So it’s one of those forbidden topics of conversation as sex is. The only time my mum ever spoke to my sister about sex was the day before her wedding day and she’s never spoken to me about it.” (SA6 HPV– normal smear)

In this context, it was not possible for women to disclose either their HPV or cytology result. For some women this was described as contributing to the anxiety that they felt following their positive result.

- “I mean the emotional pressure that you are under, I mean nobody knows that I have a partner, and then to find out that you have something like this, you just think to yourself maybe I shouldn’t have done this in the first place and then I wouldn’t be in this situation today. So there is all this guilt as well as everything else.” (SA2 HPV+ normal smear)

However, other south Asian women seemed comfortable in excluding their parents from discussions that in any way related to sex or relationships, instead they gained social and emotional support from their friends, sisters, and partners.

In contrast, African Caribbean and white British women rarely spoke about hiding information on standard cervical screening, and most of them seemed reasonably comfortable discussing an abnormal smear result. However, they were concerned about disclosing to others that they had HPV. As such, HPV testing presented a change to how and with whom their cervical screening results were discussed, in effect becoming stigmatised and taboo, not dissimilar to the south Asian women’s response to smears. There were also similarities between the south Asian group and the white British and African Caribbean women with strong religious beliefs. Among these women there was some existing stigma around an abnormal smear, and a direct link with sexual activity and promiscuity.

- “I had this association in my head, an old Catholic thing that um … promiscuity and cell changes would go together.” (W17 HPV+ CIN2)

Understanding of HPV

Although understanding that HPV was sexually transmitted was central to women’s response, there were other key features of knowledge about HPV that also seemed to be closely associated with the psychological and social burden imposed by the infection.” Understanding that HPV is an extremely common infection and can potentially clear up on its own appeared to reduce the stigma and embarrassment some women felt. Indeed, HPV was likened to infections that, while possibly sexually transmitted, are common and accepted such as candida.

- “I was under the belief that it could go away on its own. I presumed that it was, because it was a common thing…um the initial thing I read…suggested that it can sort of clear up on its own.” (W7 HPV+ normal smear)

Awareness that there are no visible physical symptoms, in particular, genital warts, and understanding that treatment for CIN is highly effective also appeared important to reassure women. In contrast, where women were still worried about the development of genital warts or confused HPV with other symptomatic STIs such as herpes, there seemed to be considerable distress.

There was also concern about the risk of spreading HPV infection and confusion about the protective role of condoms. One participant described having sex with a new partner when the condom broke.

- “I was absolutely terrified that I would pass on the infection.” (W23 HPV+ CIN2)

Another woman described concern that she had passed HPV to her ex-partner during unprotected sex. She was unsure and worried whether to inform him so that he could warn future partners of the risk. Understanding that the impact of HPV on men was negligible and condoms did not necessarily prevent infection therefore appeared to alleviate considerable anxiety. Importantly, it meant that there was no
necessity to inform sexual partners about the infection, which allowed women to avoid the challenges of disclosure, such as component, fear about rejection, and damage to their reputation. Understanding of the limits of condoms also seemed to help women feel less to blame for contracting or passing on the HPV infection.

It was also apparent in case understanding of the virus among partners, family, and friends enhanced anxiety around disclosure. In some cases women had to challenge prejudiced beliefs and defend their reputations to others armed with only a little information. Taking on the burden of explaining something poorly understood, particularly to a partner, was described as extremely difficult. Women also reported receiving inconsistent information from health professionals, which contributed to their confusion and distress about the infection.

"What really, really bothered me was the lack of consistent clear information... one health clinic in one hospital, they would say right this can be completely clear up. And then I'd speak to some other and they'd say no don't be silly it's a virus you've got it for life. And then someone else would say you're going to get warts and someone else would say you're not going to get warts it's a different strain of the virus. And someone would say a condom will not protect you it's sexually transmitted. And I would say what's the protocol here? Should I be telling sexual partners that I have this? And one person would say yes of course you must and another would say don't be silly almost all the population's been exposed to it. And there was such a conflict of information, that was what really upset me. I couldn't get to the truth ....they were giving me conflicting advice. I found that very distressing that I couldn't actually get real information that I could trust." (W17 HPV+ normal smear)

CONCLUSION

The findings suggest that testing positive for HPV was associated with adverse social and psychological consequences that were beyond those experienced by an abnormal smear alone. These related primarily to the sexually transmitted nature of the virus, which led to stigma and anxiety about the virus and concern about sexual relationships. In particular, women were worried about disclosing their result to their partner and their family, restricting their usual channels of support. Although anxiety about the infection was widespread, the impact of testing positive varied in relation to the women's relationship experience, social and cultural norms, and practices around sex and relationships, and women's understanding of key features of the virus.

The findings of this qualitative study are highly consistent with quantitative studies of the psychological impact of HPV infection and other STIs. They also contribute to our understanding of the underlying processes influencing psychological and social responses and provide a starting point to explain the variation in women's response through their relationships, norms, and understanding of HPV. The study is strengthened by its inclusion of a socially and ethnically heterogeneous sample who had participated in HPV testing in a variety of clinical settings, and the use of a qualitative approach to understand the complexities of how women respond to HPV infection. The results suggest that HPV testing imposes an additional social and psychological burden on women beyond that already experienced in conventional cytology screening and the findings have implications for plans to include HPV testing in national cervical screening programmes in the United Kingdom and worldwide.

The results highlight the crucial role of information about HPV in moderating the experience of women taking part in testing. It suggests that clear consistent information about key features of HPV, such as its high prevalence, the distinction between high risk types and genital warts, and the implications for sexual partners and disclosure, may alleviate some important anxieties. This hypothesis needs to be carefully tested, but on the basis of the results it seems that clear standardised information should be made available and screening providers should consider carefully the information and advice they give to women participating in cervical screening. The burden of information provision may fall to general practitioners (GPs) who carry out the majority of smear tests in the United Kingdom and in many other countries. It is well known that GPs find discussion of sex and STIs with patients extremely difficult, particularly with older patients, so support may be important.

HPV testing is complex for lay people and health professionals alike. The challenge will be to communicate information to women in a way that ensures they understand the facts while limiting their anxiety and the sense of stigma around the infection. We have a responsibility to ensure that women who are encouraged to participate in cervical screening and HPV testing are adequately informed so that the social and psychological harm of detecting HPV is minimised.

ACKNOWLEDGEMENTS

We are grateful to the women who took part in the study as well as Nasreen Ali, Ama de-Graft-Aikins, Salma Choudry, Glendean Morton, and Gillian Elam for assistance with interviewing; and to Caroline Cross and Liz Edmondson for interview transcription. We would also like to thank Anne Szarewski, Henry Kitchener, Rosanne Jelly, Hilda Dunsmore, Ali Kubba, and Ian Jacobs for their collaboration in allowing us access to their patients.

CONTRIBUTORS

KM, JN, and JW conceived the study; KM, JoW, JN, and JW developed the interview topic guide; KM and JoW carried out and supervised the fieldwork; KM, JoW, and JN carried out the analysis; KM wrote the first draft of the paper; all authors commented on and contributed to the final draft; KM is the guarantor.

Authors' affiliations

K McCaffrey, Screening and Test Evaluation Program, School of Public Health, Edward Ford Building (A27), University of Sydney, NSW 2006, Australia
J Waller, J Wardle, Cancer Research UK, Health Behaviour Unit, Department of Epidemiology and Public Health, UCL, 2-16 Torrington Place, London WC1E 6BT, UK
J Nazroo, Department of Epidemiology and Public Health, UCL, 1-19 Torrington Place, London WC1E 6BT, UK

Funding: The study was funded by Cancer Research UK.

Competing interest: All authors declare that there are no competing interests.

Ethical approval: The study was approved by the North and West Multi-Centre Research Ethics Committee and local ethics committees for each centre.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
REFERENCES

1. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293–9.

2. Kjaer SK, van den Brule AJC, Powell G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572.

3. Sasiens P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J Med Screen 2002;9:49–51.

4. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372–81.

5. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304–9.

6. Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120–9.

7. Wise J. UK pilot scheme for HPV testing announced. BMJ 2000;320:600.

8. Little J. Human papillomavirus testing. Effectiveness of testing for high risk HPV for triage of low grade abnormal smears is being assessed in TOMBOOLA trial BMJ 2001;323:109.

9. Schiffman M, Adnan Zar E. ASCUS-LSIL triage study. Design, methods and characteristics of trial participants. Acta Cytol 2000;44:726–42.

10. McCaffery KJ, Waller J, Forrest S, et al. Testing for human papillomavirus in women with abnormal pap smear results. JAMA 2002;288:1330; discussion 1331–2.

11. Summers A. Mental health consequences of cervical screening. Psychol Health Med 1998;3:113–26.

12. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. Br J Obstet Gynaecol 2002;109:364–8.

13. Anshang R, Wright TC Jr, Smock L, et al. Women’s desired information about human papillomavirus. Cancer 2004;100:315–20.

14. Waller J, McCaffery K, Wardle J. Beliefs about the risk factors for cervical cancer in a British population sample. Prev Med 2004;38:745–53.

15. Yokac E, Tennant C, Ferrante J, et al. University students’ knowledge and awareness of HPV. Prev Med 1999;28:515–41.

16. Duncan B, Hart G, Scoular A, et al. Qualitative analysis of psychosocial impact of diagnosis of Chlamydia trachomatis: implications for screening. BMJ 2001;322:195–9.

17. Maw RD, Raimo M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571–8.

18. IARC. International Agency for Research on Cancer Cervix Cancer Meeting, 20–27 April. Recommendations for public health implementation and further research. Lyon: WHO, 2004.

19. Waller J, McCaffery KJ, Forrest S, et al. Human papillomavirus and cervical cancer: issues for biobehavioral and psychosocial research. Ann Behav Med 2004;27:68–79.

20. Maisai M, Martou TM, Hankins M, et al. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ 2004;328:1293–9.

21. McCaffery K, Waller J, Forrest S, et al. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. Br J Obstet Gynaecol 2004;111:1437–43.

22. McCaffery K, Forrest S, Waller J, et al. Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. Br J Cancer 2003;88:42–6.

23. Coyne IT. Sampling in qualitative research: Purposeful and theoretical sampling; merging or clear boundaries? J Adv Nurs 1997;26:623–30.

24. Elam G FK, Johnson A, Nazroo J, et al. Exploring ethnicity and sexual health. London: SCPR, 1999.

25. Health Education Authority. Black and minority ethnic groups in England: health and health services. London: HEA, 1994.

26. Ritchie J SL, O’Connor W. Carrying out qualitative analysis. In: Ritchie JSL, eds. Qualitative research practice: a guide for social science students and researchers. London: Sage Publications, 2003:219–62.

27. Waller J, McCaffery K, Nazroo J, et al. Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer 2005;92:265–70.

28. Melville J, Sniffen S, Crosby R, et al. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sex Transm Infect 2003;79:280–5.

29. Smith A, Denham J, Keogh L, et al. Psychosocial impact of type-specific herpes simplex serological testing on asymptomatic sexual health clinic attendees. Int J STD AIDS 2000;11:15–20.

30. Verhoeven V, Boeijn K, Halder A, et al. Discussing STIs: doctors are from Mars, patients from Venus. Fam Pract 2003;20:11–15.

31. Gott M, Hitchcliff S, Galena E. General practitioner attitudes to discussing sexual health issues with older people. Soc Sci Med 2004;58:2093–103.